How long does 25I-NBOH last?

The total duration of 25I-NBOH via sublingual is 5 hours to 8 hours. Onset typically occurs within 15 minutes to 1 hour. Peak effects last 2 hours to 3.5 hours.

25I-NBOH — SubstanceWiki

25I-NBOH (2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine) is a synthetic psychedelic phenethylamine belonging to the NBOH series and representing the direct NBOH analog of 25I-NBOMe — the most potent and most dangerous of the major NBOMe compounds. It is active at microgram doses through potent 5-HT2A agonism and is only active via sublingual or buccal administration.

25I-NBOH represents the iodinated member of the NBOH series, and within the NBOH family it is expected to be among the most potent based on the consistent structure-activity relationship seen across the 2C and NBOMe series: 4-iodo substitution generally confers the highest 5-HT2A binding affinity among the common 4-halo variants. The compound's pharmacology is broadly described as very similar to 25I-NBOMe but with lower physical toxicity — the 2-hydroxybenzyl group appears to reduce the severe vasoconstriction associated with the 2-methoxybenzyl group of NBOMe compounds.

No confirmed fatalities specifically from 25I-NBOH have been documented, representing a meaningful contrast to 25I-NBOMe which has one of the highest confirmed death tolls among novel psychoactive substances. However, this relative safety advantage does not eliminate risk: 25I-NBOH is extremely potent, carries all the characteristic hazards of microgram-dosed psychedelics with steep dose-response curves, and is physically indistinguishable from NBOMe blotters without testing. Any blotter that tests negative for indoles should not be assumed to be the "safer" NBOH variant.

How It Feels

Within twenty minutes, a sharpening of the visual field announces the arrival of the experience. Colors begin to pop with increasing intensity -- reds deepen, greens fluoresce, and blues acquire an electric depth. A mild stimulant energy builds in the chest and limbs, but it carries none of the vasoconstriction-heavy body load that makes its NBOMe counterpart so physically demanding. The body feels energized but not wired, alert but not tense. There is an anticipatory excitement as the visual effects begin to accelerate.

By the one-hour mark, the visual component has blossomed into something spectacular. 25I-NBOH is among the most visually potent compounds in the NBOx series, and at the peak it delivers a torrent of geometric complexity that rivals 25I-NBOMe without the punishing physical cost. Intricate, symmetrical patterns tile across every surface -- elaborate mandalas, crystalline lattices, and spiraling fractals that pulse and shift with mechanical precision. Colors are vivid beyond natural possibility, glowing with an internal luminance that makes the world appear rendered in stained glass. Afterimages trail behind moving objects in prismatic ribbons. The visual field seems to contain more information than the eyes normally process, as though the brain's pattern-recognition systems have been pushed into overdrive.

The headspace is remarkably clear for the level of visual intensity. Thoughts are lucid, organized, and gently accelerated. There is a euphoric brightness to the mood -- a sense of wonder and engagement with the visual spectacle that maintains its novelty throughout the peak. Music is dramatically enhanced, with sounds seeming to generate visual counterparts in real time. Socially, the experience lends itself to animated conversation and shared exploration of the altered perceptual landscape. The body load, while not absent, is manageable: mild jaw tension, a slight elevation in heart rate, and occasional waves of warmth. Compared to 25I-NBOMe, the physical experience is noticeably more comfortable, allowing greater attention to be directed toward the extraordinary visual content.

The peak sustains for two to three hours before gradually subsiding. The geometric overlays thin and eventually fade, leaving behind hours of enhanced color perception and gentle visual shimmer. The stimulant component eases into a calm alertness. Total duration spans six to eight hours. The comedown is smooth and the aftermath is surprisingly clean -- mild fatigue, perhaps, but little of the physical wreckage that the NBOMe compounds can leave in their wake.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(15)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Cognitive & Perceptual Effects

Visual(20)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...

Detection Methods

Urine Detection

25I-NBOH is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOH compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.

Blood and Serum Detection

Blood detection windows for 25I-NBOH are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOH compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.

Standard Drug Panel Inclusion

25I-NBOH is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.

Confirmatory Methods

Definitive identification of 25I-NBOH requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOH compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.

Reagent Testing (Harm Reduction)

Reagent testing is critically important for NBOH compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25I-NBOH, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOH compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOH compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOH compound.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Acute Toxicity Profile

No confirmed fatalities specifically attributed to 25I-NBOH alone have been documented in the scientific literature. This contrasts with 25I-NBOMe, which has one of the highest confirmed death tolls among novel psychoactive substances. The NBOH modification is believed to reduce severe vasoconstriction risk relative to NBOMe, which is the primary mechanism of acute fatality.

Vasoconstriction

While less severe than NBOMe compounds, vasoconstriction remains a documented and clinically significant effect of NBOH compounds, including 25I-NBOH. It manifests as cold, pale, or blue extremities and is exacerbated by stimulant co-use.

Cardiovascular Effects

Tachycardia and elevated blood pressure are expected effects. Those with cardiovascular conditions are at elevated risk.

Psychological Risks

25I-NBOH can produce very intense psychedelic experiences at modest doses due to its high potency. Acute panic, paranoia, and psychological crisis are documented adverse events.

Drug Interactions

Stimulants — Strongly contraindicated; compound vasoconstriction
Lithium — Absolutely contraindicated
MAOIs — Avoid; serotonin syndrome risk
Cannabis — Dramatically amplifies intensity; significant crisis risk

Contraindications

Cardiovascular disease or vascular disorders
Personal or family history of psychotic disorders
Current use of stimulants, lithium, or MAOIs

Addiction Potential

not habit-forming

Overdose Information

LD50potentially fatal at heavy dosages.

25I-NBOH's extreme potency means it should not be insufflated (snorted) as this method of administration has been associated with many deaths and hospitalizations with the closely related 25I-NBOMe.

25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumption). 25I-NBOH presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25I-NBOH all psychedelics will have a reduced effect.

Germany: 25I-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Sweden: The Riksdag added 25I-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12
Switzerland: 25I-NBOH is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 25I-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
Responsible use
Research chemical
Psychedelics
Phenethylamines
25x-NBOH
25I-NBOMe
25I-NBOH (Wikipedia)
25I-NBOH (Isomer Design)
The Big & Dandy 25I-NBOH Thread (Bluelight)

==Refe

Full	almost immediately after ingestion
Half	1 week
Zero	2 weeks

25I-NBOH

Quick Dosage

Dosage

sublingual

Duration

sublingual

How It Feels

Subjective Effects

Physical Effects

Physical(15)

Cognitive & Perceptual Effects

Visual(20)

Pharmacology

Mechanism of Action

NBOH vs NBOMe Pharmacology

Route of Administration

Pharmacokinetics

Tolerance

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Development

Research Context

Prevalence

Legal Status

Harm Reduction

Do Not Assume NBOH is Safe

Test Your Substance

Sublingual Administration Only

Conservative Dosing

Monitor for Vasoconstriction

Dangerous Combinations to Avoid

Toxicity & Safety

Acute Toxicity Profile

Vasoconstriction

Cardiovascular Effects

Psychological Risks

Drug Interactions

Contraindications

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

Similar by Effects

Same Class

References (4)

Frequently Asked Questions

Cognitive(15)

Auditory(3)

Multi-sensory(2)

Transpersonal(3)